Webinar | Application of BRET Technology to Quantitatively Determine Kinase Inhibitor Potency in Live Cells

 

Application of BRET Technology to Quantitatively Determine Kinase Inhibitor Potency in Live Cells

Tuesday, November 6, 2018
View registration for sessions available
Presented by:

Matthew Robers
Senior Research Scientist and Group Leader, Promega Corporation

and

Kelvin Lam
Senior Director of Business Development, Reaction Biology Corporation

Learn how to overcome the limitations of current cell-based kinase assays by enabling quantitation of kinase-inhibitor occupancy and affinity in live cells.

In addition, learn about the collaboration between Promega and Reaction Biology Corporation resulting in conversion of BRET-based kinase target engagement assays into a service compatible with high-throughput cell-based profiling.

 

 

 

Register for Webinar ›

Next article Webinar | Ensuring a Successful PCR Every Time